These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 24634469)

  • 41. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
    Love D; Stratton E; Stocum M
    N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Do companion diagnostics make economic sense for drug developers?
    Agarwal A
    N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New scenario in the field of medical devices in the European Union: Switzerland and the United Kingdom become third countries.
    Fraga-García M; Taléns-Visconti R; Nácher-Alonso A; Díez-Sales O
    Farm Hosp; 2022 Jun; 46(4):244-250. PubMed ID: 36183222
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Companion diagnostics in oncology - current status and future aspects.
    Jørgensen JT
    Oncology; 2013; 85(1):59-68. PubMed ID: 23860090
    [TBL] [Abstract][Full Text] [Related]  

  • 45. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
    Rose K
    Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular diagnostics: an FDA perspective.
    Ardekani AM; Petricoin EF; Hackett JL
    Expert Rev Mol Diagn; 2003 Mar; 3(2):129-40. PubMed ID: 12647991
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Value of Companion Diagnostics: Overcoming Access Barriers to Transform Personalised Health Care into an Affordable Reality in Europe.
    Wurcel V; Perche O; Lesteven D; Williams DA; Schäfer B; Hopley C; Jungwirth R; Postulka A; Pasmans R; Hermansson LL; Ott M; Glorioso V
    Public Health Genomics; 2016; 19(3):137-43. PubMed ID: 27237134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
    Parkinson DR; Johnson BE; Sledge GW
    Clin Cancer Res; 2012 Feb; 18(3):619-24. PubMed ID: 22298894
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular tools for companion diagnostics.
    Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
    N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Introduction to in vitro diagnostic device regulatory requirements.
    Day J
    Methods Mol Biol; 2013; 949():103-12. PubMed ID: 23329438
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The new European directive on in vitro diagnostics.
    Dati F
    Clin Chem Lab Med; 2003 Oct; 41(10):1289-98. PubMed ID: 14580154
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Companion and complementary diagnostics for infectious diseases.
    Dailey PJ; Elbeik T; Holodniy M
    Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform. Report of a policy conference of the European Society of Cardiology.
    Fraser AG; Daubert JC; Van de Werf F; Estes NA; Smith SC; Krucoff MW; Vardas PE; Komajda M;
    Eur Heart J; 2011 Jul; 32(13):1673-86. PubMed ID: 21572115
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 56. EU alerting and reporting systems for potential chemical public health threats and hazards.
    Orford R; Crabbe H; Hague C; Schaper A; Duarte-Davidson R
    Environ Int; 2014 Nov; 72():15-25. PubMed ID: 25023642
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overcoming regulatory and economic challenges facing pharmacogenomics.
    Cohen JP
    N Biotechnol; 2012 Sep; 29(6):751-6. PubMed ID: 22370122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Paediatric drug development: the impact of evolving regulations.
    Turner MA; Catapano M; Hirschfeld S; Giaquinto C;
    Adv Drug Deliv Rev; 2014 Jun; 73():2-13. PubMed ID: 24556465
    [TBL] [Abstract][Full Text] [Related]  

  • 59. European regulations on nutraceuticals, dietary supplements and functional foods: a framework based on safety.
    Coppens P; da Silva MF; Pettman S
    Toxicology; 2006 Apr; 221(1):59-74. PubMed ID: 16469424
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.